Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Use of PET Scans with Fludeoxyglucose (18F) for Diagnosing Endometriosis in Patients with Symptoms

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the condition known as endometriosis, which is a painful disorder where tissue similar to the lining inside the uterus grows outside the uterus. The study aims to evaluate the effectiveness of a special type of scan called a positron emission tomography (PET) scan in identifying endometriosis lesions before surgery. The PET scan will be compared to the findings from surgery to see how well it can detect the number and location of these lesions.

During the study, participants will undergo a PET scan using a substance called fludeoxyglucose (18F), which helps highlight areas of concern in the body. This is a solution that is injected into the body and is designed to make the PET scan images clearer. The study will also use a solution called Furosemide, which is a medication that helps the body get rid of excess fluid, and Omnipaque, a contrast agent that improves the visibility of internal structures in imaging tests.

The purpose of the study is to determine if the PET scan can accurately diagnose endometriosis lesions compared to traditional surgical methods. Participants will receive these injections and undergo the PET scan, and the results will be compared to what is found during surgery. This research could help improve the way endometriosis is diagnosed and managed in the future.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    The trial begins with an initial assessment to confirm eligibility. This includes verifying age, symptoms, and the presence of endometriosis lesions greater than 5mm on an MRI scan.

    Eligibility criteria include being aged over 18 and under 50, having symptomatic endometriosis with an indication for surgery, and having signed an informed consent form.

  2. Step 2

    Preparation for PET scan

    Preparation involves the administration of fludeoxyglucose (18f), a radioactive substance used in PET scans. This is given as an intravenous injection.

    The purpose of this step is to enhance the visibility of endometriosis lesions during the PET scan.

  3. Step 3

    PET scan procedure

    A positron emission tomography (PET) scan is conducted to assess the number and location of endometriosis lesions.

    The scan aims to provide detailed images that help in diagnosing endometriosis lesions compared to surgery.

  4. Step 4

    Administration of furosemide

    Furosemide, a diuretic, is administered as a 10 mg/ml solution for injection. This is given intravenously to help clear the radioactive substance from the body after the PET scan.

  5. Step 5

    Administration of iohexol

    Iohexol, a contrast agent, is administered as Omnipaque 350 mg I/ml solution for injection. This is used to enhance imaging results.

    The injection is given intravenously to improve the clarity of the images obtained during the scan.

  6. Step 6

    Surgical assessment

    Surgical assessment is conducted to compare the findings from the PET scan with the actual number and location of endometriosis lesions.

    This step is crucial for evaluating the effectiveness of the PET scan in diagnosing endometriosis.

  7. Step 7

    Follow-up and analysis

    Follow-up involves analyzing the data collected from the PET scan and surgical assessment.

    The primary goal is to determine the total number of lesions diagnosed by the PET scan compared to surgery, and to identify any additional lesions visible on the PET scan but not on the MRI.

Who can join the trial?

6 criteria

  • Patient must be a woman aged over 18 and under 50.
  • Patient must have **symptomatic endometriosis**, which means experiencing symptoms of endometriosis, and must need surgery.
  • Patient must show at least one typical **endometriosis lesion** on an **MRI** scan, which is a special imaging test, and the lesion must be greater than 5mm in size.
  • Patient must agree to undergo surgical treatment.
  • Patient must have signed an **informed consent**, which means they have been given information about the study and agree to participate.
  • Patient must be affiliated with or a beneficiary of a social security scheme, which means they have some form of health insurance or coverage.

Who cannot join the trial?

3 criteria

  • Only females can participate in the study. Males are excluded.
  • Participants must be within a specific age range. If you are outside this range, you cannot join the study.
  • Individuals who are considered part of a vulnerable population are not allowed to participate. A vulnerable population includes people who might have difficulty giving informed consent or are at higher risk of harm.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

PET Scan is a type of imaging test that helps doctors see how the tissues and organs inside your body are functioning. In this trial, it is used to help diagnose endometriosis lesions by providing detailed images that can show the presence and location of these lesions before surgery.

What is already known about the treatment

Leuprorelin – This medication is administered via injection and is used in the treatment of endometriosis. It is currently well-documented in medical literature as an effective therapy for managing symptoms associated with this condition. Leuprorelin works by reducing the production of certain hormones in the body, which helps to decrease the growth of endometrial tissue. It is classified as a gonadotropin-releasing hormone (GnRH) agonist.

Investigated diseases

Endometriosis – Endometriosis is a condition where tissue similar to the lining inside the uterus starts to grow outside the uterus. This misplaced tissue can be found on the ovaries, fallopian tubes, and the outer surface of the uterus, as well as other organs in the pelvis. The tissue behaves like normal uterine tissue, thickening, breaking down, and bleeding with each menstrual cycle. However, because it has no way to exit the body, it becomes trapped, leading to inflammation and the formation of scar tissue. Over time, this can cause pain, especially during menstruation, and may lead to fertility problems. The severity of symptoms can vary widely among individuals.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-520423-88-00Protocol code2013/CHU/12Estimated enrolment15 patientsSponsorCentre Hospitalier Universitaire De La Reunion

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).